AZ Q2 Preview: Pipeline, COVID-19 and M&A Key Focus

Oncology Drugs Will Be Growth Drivers

AstraZeneca’s half-year results, out on 30 July, will be keenly watched due to the pharma’s attractive near-term growth, pipeline catalysts and its promising COVID-19 vaccine. 

AZ
AZ’s pipeline is emerging as one of the strongest in the pharma sector • Source: Shutterstock

AstraZeneca PLC’s recent and coming launches of new drugs and its expanding pipeline, along with a big presence in China and the promising vaccine that is being developed against SARS-CoV-2 virus in partnership with Oxford University, should ensure keen investor interest when the UK-based drugmaker reports second quarter and half-year results on 30 July. 

The company has returned to financial growth on the back of a rejuvenated pipeline and new drug offerings that are...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Earnings

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.